Drug Trial Radar · NCT05885841
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD
Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Feb 15, 2022
Primary completion
May 9, 2023
Study completion May 9, 2023
Sponsor
- Lead sponsor
- Sinotau Pharmaceutical GroupIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The diagnostic efficacy and safety of the XTR004 myocardial perfusion PET imaging tracer are evaluated for known or suspected CAD with the use of invasive coronary angiography as the reference standard for the diagnosis of CAD and invasive pressure-temperature FFR/IMR as a reference for the detection of abnormal coronary function.
Conditions
- Coronary Artery Disease (CAD)
Interventions
XTR004Drug
At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Qualitative reading and semi-qualitative MPI analysis (SSS and SDS)Time frame: Day 1
- Quantitative index of XTR004 PET myocardial blood flow (Stress MBF, MFR)Time frame: Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.